“…MT can serve as a prognostic marker in central nervous system tumors of childhood and adolescence (Rickert and Paulus, 2005;Rickert, 2004), osteosarcoma (Trieb and Kotz, 2001), breast cancer (Woolston et al, 2010;Jin et al, 2004;Gomulkiewicz et al, 2010), pancreatic islet cell tumors (Tomita, 2002), and tongue squamous-cell carcinoma (Theocharis et al, 2011). MT can also serve as a serum tumor marker in prostate cancer Masarik et al, 2011), head and neck tumors , childhood solid tumors , and melanoma . Expression of MT may help to distinguish between benign and malignant tumor, as shown in thyroid tumors (Krolicka et al, 2010), prostatic lesions (El Sharkawy et al, 2006), GI stromal tumors, and gastric carcinomas (Soo et al, 2011).…”